Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Asthma Control in General Practice
Jean Holohan,Pat Manning +1 more
TL;DR: A worldwide network of individuals, organisations, and public health officials to disseminate information about the care of patients with asthma while at the same time assuring a mechanism to incorporate the results of scientific investigations into asthma care using evidence-based knowledge.
Effets rhino sinusiens des biothérapies chez l'asthmatique sévère
TL;DR: Les biotherapies indiquees dans l’asthme severe de type anti IL5 et anti IgE ont egalement une efficacite sur les symptomes de rhinosinusite chronique, avec un impact majeur sur la qualite de vie des patients.
Journal ArticleDOI
The many faces of severe asthma.
TL;DR: In the present issue of Allergy several original contributions provide novel information on difficult asthma phenotypes, both in adults and in children.
Book ChapterDOI
Medical Management of Asthma
Andrej A. Petrov,Sally E. Wenzel +1 more
TL;DR: According to a new classification, patients with asthma should be categorized as controlled, partly controlled or uncontrolled, which recognizes that asthma is a disease with variable presentation where an individual’s asthma symptoms may change over months or years.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.